ArticleJournal of pharmaceutical policy and practice2025
Effectiveness of a multidisciplinary team-delivered deprescribing intervention for patients with chronic kidney disease: a protocol for a randomised controlled trial.
Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06324045 (Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial
Who cites it
1 citing paper in PubMed.
- Development and validation of deprescribing algorithms for kidney failure using consensus development methodology.Journal of pharmaceutical policy and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inappropriate polypharmacy is prevalent among patients with chronic kidney disease (CKD), and can be mitigated by deprescribing. We aim to evaluate the clinical and economic impact of a multidisciplinary deprescribing programme in Qatar's healthcare system. Methods: This randomised controlled trial will be conducted at ambulatory dialysis centres, with an internal pilot to assess the feasibility of recruitment, intervention implementation, and safety measures. Patients will be randomised to usual care or an intervention group where a clinical pharmacist, in collaboration with a multidisciplinary healthcare team, will deliver a structured deprescribing intervention, including periodic monitoring over six months. Outcomes will be measured at baseline, three, and six months. The primary outcome is the proportion of patients with at least one potentially inappropriate medication (PIM). Secondary outcomes include pill burden, treatment burden, hospitalisations, emergency department visits, quality of life, and adherence. A cost-benefit analysis will also be performed. A total of 250 patients provides 90% power to detect a 50% reduction in PIM prevalence (α = 0.05). The statistical analysis will be based on the intention-to-treat principle, using mixed-effects models to account for repeated measures. Discussion: Findings will provide novel evidence on deprescribing in CKD, informing future clinical and policy interventions. Trial Registration: ClinicalTrial.gov. NCT06324045. Registered on 15 March 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.